FDA Warns L'Oreal's Lancome Unit on Anti-Wrinkle Product Marketing

The U.S. Food and Drug Administration warned L'Oreal SA's (OR.FR) Lancome USA unit about the marketing of certain anti-wrinkle products, saying the products are marketed with claims suggesting they are drugs. The letter discussed the marketing of several products--including Lancome's Genifique Youth Activating Concentrate and Renergie Microlift Eye R.A.R.E. Intense Repositioning Eye Lifter--and said claims suggesting the products "boosts the activity of genes and stimulates the production of youth proteins" or provide "immediate lifting" to the eye area, violate federal drug laws.